Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019 Read more about Iovance Biotherapeutics to Host Fourth Quarter and Year-End 2018 Financial Results Conference Call and Webcast on Wednesday, February 27, 2019
Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Investor and Medical Conferences
Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference Read more about Iovance Biotherapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Iovance Biotherapeutics to Participate at November Investor Conferences Read more about Iovance Biotherapeutics to Participate at November Investor Conferences
Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting Read more about Iovance Biotherapeutics Announces Updated Phase 2 Clinical Data from the Lifileucel Metastatic Melanoma Trial at the Society for Immunotherapy of Cancer’s 33rd Annual Meeting
Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018 Read more about Iovance Biotherapeutics to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Tuesday, November 6, 2018
Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018 Read more about Iovance Biotherapeutics to Host Melanoma Program Update Event for Analysts and Investors During SITC 2018
Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe Read more about Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe
Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $252 Million Common Stock Public Offering